June 1, 2011
PLEASE SIGN THE FAMEDS PETITION
If you have not had the opportunity to do so prior to now, please sign the FAMEDS petition at www.fameds.org/petition.php
. Thank you for your support – it is vital to the Avastin women that they know that you stand with them in this battle.
IF YOU ARE AN AVASTIN PATIENT OR A CLOSE RELATIVE, PLEASE CONTACT US
It is crucial that the Avastin story be told and the best people to tell the world about the importance of Avastin are the patients themselves and their close / immediate families. If you have a video that we can post or a photo with a letter, we would love to hear from you. Please contact us at firstname.lastname@example.org
or call us at 248.761.8215. We are on EST.
FAMEDS ON LOCAL ABC AFFILIATE IN MICHIGAN
FAMEDS AVASTIN PROTEST CALL SET FOR THURSDAY, JUNE 2 AT 8 PM EST
We shall hold a protest outside the FDA headquarters in Silver Spring, Maryland on June 28th, from 7 a.m. to 8 a.m. For those interested in attending, the sign-up sheet is live on our website at http://www.fameds.org/protest.php
We shall hold an organizing meeting for the protest at 8 pm EST on Thursday, June 2rd and it will run a maximum of 30 minutes. For those that wish to participate, here are the call-in details:
Conference Dial-in Number: (605) 475-4000
Participant Access Code: 586521#
HAVE YOU FRIENDED US ON FACEBOOK OR JOINED US ON LINKEDIN, ETC?
FREEDOM OF ACCESS TO MEDICINES - AVASTIN BLOG
Freedom of Access to Medicines has established a dedicated place to discuss all issues related to Avastin at: myfameds.blogspot.com
Please start presenting your opinions.
HEARING ON PROPOSAL TO WITHDRAW APPROVAL FOR THE BREAST CANCER INDICATION FOR BEVACIZUMAB (AVASTIN)
The Food and Drug Administration (FDA) is granting a hearing to Genentech, Inc., on the Center for Drug Evaluation and Research's (CDER's) proposal to withdraw accelerated approval of the breast cancer indication for bevacizumab (Avastin). Genentech and CDER are the parties to the hearing.
June 28-29, 2011
8:00 a.m. – 5:00 p.m.
FDA White Oak Campus, 10903 New Hampshire Ave. Bldg. 31, Great Room, Silver Spring, MD 20993
is available on Regulations.gov
. All documents filed or posted in this matter are available for public review under Docket No. FDA-2010-N-0621 in the Division of Dockets Management, Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday.
Federal Register Notice
Attendance and Webcast
If you wish to attend the hearing or view the hearing via webcast, you must register with FDA in advance of the hearing. If you wish to register for either attendance in person or the webcast, you should return to this page: (http://www.fda.gov/NewsEvents/MeetingsConferencesWorkshops/ucm255874.htm)
, at 10:00 a.m. EDT on May 27, 2011. At that time, links for online registration will be available.
You will receive a confirmation e-mail if your registration is successful.
The public meeting is free. Seating is limited to 300 persons from the general public. Availability via webcast will be limited to a certain number of persons. FDA asks that you do not register for both attending the hearing in person and viewing the webcast.
You may submit electronic or written comments to Regulations.gov
. Comments must be submitted by July 14, 2011. You may also submit written comments to the Division of Dockets Management, (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852.